✓ Translated by DotMD AI Clinical Council Source: Expert review of gastroenterology & hepatology • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #39909733 ↗

Phase III Randomized Trial: Dupilumab is efficacious for eosinophilic esophagitis irrespective of prior swallowed budesonide or fluticasone, or prior treatments used alongside swallowed topical corticosteroids: results from the phase 3, randomized, placebo-controlled, LIBERTY EoE TREET trial

Original Paper Title: “Dupilumab is efficacious for eosinophilic esophagitis irrespective of prior swallowed budesonide or fluticasone, or prior treatments used alongside swallowed topical corticosteroids: results from the phase 3, randomized, placebo-controlled, LIBERTY EoE TREET trial”

Elena Rostova (AI Quant) Rigor Score
88 / 100
Sample Size (Participants)
Systematic Review
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • Dupilumab was efficacious in patients with EoE irrespective of prior treatments/interventions.
  • Study Design & Sample: Phase III Randomized Trial published in Expert review of gastroenterology & hepatology (Multi-cohort synthesis).
  • Biostatistical Rigor Score: 88/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Expert review of gastroenterology & hepatology (2025), this phase iii randomized trial evaluating human clinical outcomes investigated: Standard treatments for eosinophilic esophagitis (EoE) may present adherence, tolerance, and efficacy challenges. Key clinical takeaway: Dupilumab was efficacious in patients with EoE irrespective of prior treatments/interventions.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Expert review of gastroenterology & hepatology, 2025-01-15; Phase III Randomized Trial; Rigor 88/100): Dupilumab was efficacious in patients with EoE irrespective of prior treatments/interventions.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: dupilumab → Rx: budesonide → Rx: budesonide-and-formoterol-fumarate → Rx: fluticasone-furoate-nasal → Condition: eosinophilic-esophagitis → Condition: steroids →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 39909733: Phase III Randomized Trial: Dupilumab is efficacious for eosinophilic esophagitis irrespective of prior swallowed budesonide or fluticasone, or prior treatments used alongside swallowed topical corticosteroids: results from the phase 3, randomized, placebo-controlled, LIBERTY EoE TREET trial

3 of 3 Free Questions Remaining